Application of cyclic astragalol in prevention and treatment of abdominal aortic aneurysm

A few days ago, a related article published by Peking University in the British Journal of Pharmacy revealed the effect of cyclic astragalol on the prevention and treatment of abdominal aortic aneurysm. An abdominal aortic aneurysm is an aneurysm-like dilatation of the abdominal aorta, usually increasing in diameter.50%The above definition is aneurysm. Although abdominal aortic aneurysm is not a true tumor, it is more harmful to the human body than various malignant tumors. Once the tumor ruptures, it can cause death in a short time. The total mortality rate is78%, approximately50%Patients have died before arriving at the hospital, even if they can successfully enter the operating room, the mortality rate is as high23% - 62%.

At present, the rupture of abdominal aortic aneurysm in our country is65One of the leading causes of death in the elderly over the age8.8%The incidence of men is higher than that of women,60The ratio of male patients over one year old is as high80%It is the most common atherosclerotic aneurysm in the human body. With the aging of the population and the continuous progress of detection methods, the incidence of abdominal aortic aneurysm has increased year by year.

The occurrence of abdominal aortic aneurysm is a complex process of multiple factors, including arteriosclerosis, abnormal protein metabolism, family inheritance, immune inflammation, apoptosis of vascular smooth muscle cells, hypertension, cardiovascular disease and smoking are the main causes of the disease. Daily patients can show occasional abdominal pain, but usually asymptomatic, a small number of patients in the discovery of the tumor has been ruptured.

Abdominal aortic aneurysm is divided into two types, large abdominal aortic aneurysm and small abdominal aortic aneurysm, the former only10%Most are small, but small abdominal aortic aneurysms are often3-5developed during the year.5 cmTherefore, the development of effective drugs to inhibit small abdominal aortic aneurysms has a good application prospect.

Drug Introduction

Cyclic astragalol (Cycloastragenol) is a triterpene saponin compound isolated from Astragalus membranaceus, which is astragaloside (AstragalosideThe main hydrolysis metabolites of IV), with a smaller molecular weight and high lipophilicity, has certain advantages in gastrointestinal absorption and biological membrane penetration, and is the only telomerase activator found today, which delays telomere shortening by increasing telomerase. Cycloastragalol is considered to have anti-aging effect.

Molecular formula:C₃₀H₅₀O₅

Domestic patent situation

Since it has been proved in animal experiments that it can significantly prolong the occurrence time of arrhythmia caused by aconitine, reduce the incidence of ventricular fibrillation and improve the survival rate of animals, Lunan Pharmaceutical Group Co., Ltd.2016A patent was applied for the use of cyclic astragalol in medicine, and both patents are currently in the substantive examination stage.

Summary

In the past, cyclic astragalol has been reported to have anti-inflammatory, anti-aging, anti-viral, anti-oxidative stress, anti-hyperlipidemia and other effects. However, the efficacy of suvastatin and other drugs used in the treatment of abdominal aortic aneurysm is not yet certain, so it can be seen that the application of Chinese medicine extract cyclic astragalol has a good prospect.